Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) is now up 35.83% compared to a 12-month low of $1.20. We have seen the price to move -8.43% lower and get settled at $1.63 on 11/06/2017. At recent session, it appeared stuck in a range of $1.54 to $1.78. This company shares are 314.11% off its target price of $6.75 and the current market capitalization stands at $17.03M. The recent change has given its price a 6.11% lead over SMA 50 and -92.75% deficit over its 52-week high. The stock witnessed -1.21% declines, 23.48% gains and -28.82% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ANTH’s volatility during a week at 10.17% and during a month it has been found around 9.12%.Anthera Pharmaceuticals, Inc. (ANTH) Top Holders
Institutional investors currently hold around $5 million or 29.2% in ANTH stock. Look at its top three institutional owners. Bvf Inc/Il owns $1.79 million in Anthera Pharmaceuticals, Inc., which represents roughly 10.52% of the company’s market cap and approximately 35.84% of the institutional ownership. Similar statistics are true for the second largest owner, Sabby Management, Llc, which owns 592,672 shares of the stock are valued at $1.06 million. The third largest holder is Vanguard Group Inc, which currently holds $607 thousand worth of this stock and that ownership represents nearly 3.56% of its market capitalization.
At the end of 06/30/2017 reporting period, 16 institutional holders increased their position in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) by some 751,065 shares, 44 decreased positions by 1,367,801 and 6 held positions by 861,789. That puts total institutional holdings at 2,980,655 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 160,887 shares while 28 institutional investors sold out their entire positions totaling 789,858 shares.Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Insider Trades
Multiple company employees have indulged in significant insider trading. Anthera Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO Thompson John Craig has acquired 8,550 shares of Anthera Pharmaceuticals, Inc. (ANTH) in trading session dated Sep. 20, 2017. These shares are worth $11,286 and were traded at $1.32 each. The SEC filing shows that Thompson John Craig performed a purchase of 10,400 shares. The President & CEO added these shares by way of transaction on Sep. 07, 2017. The company’s shares were assimilated at $1.43 per share worth to an investment of some $14,872 on account of Thompson John Craig.
Director, Truex Paul F, purchased 5,000 common shares of Anthera Pharmaceuticals, Inc. (ANTH) in the open market. In a transaction dated Sep. 07, 2017, the shares were bought at an average price of $1.34, giving away a sum of $6,700. After this purchase, 16,793 common shares of ANTH are directly owned by the insider, with total stake valued at $27,373.
In the transaction dated Nov. 13, 2015, the great number of shares disposed came courtesy the Chief Medical Officer; Hislop Colin disposed a total of 1,563 shares at an average price of $42.48, amounting to approximately $66,396. The insider now directly owns 2,631 shares worth $4,289.Anthera Pharmaceuticals, Inc. (ANTH) Analyst Guide
Several analysts have released their opinion on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.33 average brokerage recommendation.